Introduction
============

The serotonin (5-HT) 5-HT~2A~ receptor (5-HT~2A~R) is a GPCR of the type A family. It was defined as the classical D receptor initially by [@B55], and later referred as the 5-HT~2~ receptor by [@B124]. The 5-HT~2A~R gene is located on human chromosome 13q14-q21. *HTR2A* gene codes for a 471-amino acid sequence in rat, mouse, and human ([@B152]). The rat 5-HT~2A~R was cloned in 1988 ([@B130]) and the human 5-HT~2A~R was reported by [@B81]. Central 5-HT~2A~Rs exert diverse behavioral, physiological, and psychological influences ([@B72]; [@B66]; [@B71]). Abnormality in the structure and function of the 5-HT~2A~R is associated with a number of disorders, including schizophrenia, depression/anxiety, and drug addiction. Furthermore, many hallucinogenic drugs exert their psychoactive effects by acting as agonists for 5-HT~2A~Rs. Preclinical studies show that 5-HT~2A~R blockade has antipsychotic ([@B108]), antidepressant ([@B88]; [@B137]) and anxiolytic properties ([@B36]). Pharmacological studies indicate that high-affinity antagonists of 5-HT~2A~Rs are effective atypical antipsychotics, due to their demonstrated efficacy to reduce both positive and negative symptoms of schizophrenia. Results from recent molecular biological and neuropharmacological studies suggest some exciting potential new avenues by which 5-HT~2A~Rs influence CNS function. Here we review progress in understanding the contribution of 5-HT~2A~Rs to modulation of learning and memory through an analysis of their (1) anatomy and biology: distribution, signaling, polymerization, and allosteric modulation; and (2) functions: learning and memory, hallucination and spatial cognition, and mental disorders. Based on the recent progress in 5-HT~2A~R research, we suggest that selective 5-HT~2A~R modulators targeting distinct signaling pathways may hold significant efficacy as new therapeutic approaches for several neurological disorders that present with cognitive impairment.

5-HT~2A~R Anatomy and Biology in CNS
====================================

Cellular and Subcellular Distribution
-------------------------------------

Serotonin 5-HT~2A~Rs are widely distributed in the CNS. In the rat brain, immunohistochemical studies show that 5-HT~2A~Rs are broadly expressed in the cerebral cortex -- especially in layers I and IV--V, the piriform and entorhinal cortex, the claustrum, endopiriform nucleus, and olfactory bulb/anterior olfactory nucleus, brainstem, as well as the limbic system and the basal ganglia; especially in the NAc and caudate nucleus ([@B178]; [@B66]). Interestingly, 5-HT~2A~R binding appears to be absent from cerebellum ([@B178]).

In human brain, autoradiographic analysis using \[^3^H\] ketanserin indicates a high density of 5-HT~2A~R binding in laminae III and V of the frontal, parietal, temporal, occipital, anterogenual cortexes, and entorhinal area. 5-HT~2A~Rs are also visualized in the mammillary bodies of the hypothalamus, claustrum, and the lateral nucleus of the amygdala. The hippocampus, caudate, putamen, and accumbens nuclei present an intermediate density of binding. Areas such as the thalamus, brain stem, cerebellum and spinal cord contained only low to very low densities of binding ([@B121]). *In situ* hybridization studies reveal that 5-HT~2A~R mRNA is present in all neocortical areas, especially in layer 5 pyramidal neurons, and in putative interneurons. 5-HT~2A~R mRNA was observed at minimal levels in the hippocampus and not in the raphe, cerebellum, substantia nigra or striatum ([@B25]).

Morphological and double immunofluorescence analyses confirmed the presence of 5-HT~2A~Rs on pyramidal neurons, interneurons, and glial cells in neocortex, amygdala and hippocampus ([@B175]; [@B19], [@B20]). Thus, predicting the functional influence of activated cortical 5-HT~2A~Rs is not straightforward, since these receptors would be capable of direct excitation and modulating feed-forward inhibition. In addition, 5-HT~2A~Rs are located on cholinergic ([@B132]) and glutamatergic neurons ([@B68]). 5-HT~2A~R immunolabeling was also observed on glial cells in many forebrain regions: astrocytes were identified by double immunolabeling as cells in which 5-HT~2A~R and GFAP was colocalized ([@B178]); and on microglia ([@B57]). These findings demonstrate that consideration of the serotonin-mediated signaling at 5-HT~2A~Rs must include pathways that involve neurons and glial cells alike. It will be of interest to determine the degree to which functional influences expressed by the activation of 5-HT~2A~Rs are dependent upon neurons, astrocytes, and microglial cells, and to determine whether clinically relevant features of 5-HT~2A~Rs are related to changes in neurons or astrocytes.

At the subcellular level, 5-HT~2A~R immunolabeling is found on cell bodies and processes of neurons ([@B40]; [@B178]); in particular, at both pre- and post-synaptic compartments ([@B113]). However, the majority of evidence suggests a predominant expression at postsynaptic dendritic spines and shafts of non-5-HT neurons. Our own immuno-electron microscopy data revealed that 5-HT~2A~R is also distributed in the dendritic spines, shafts, and presynaptic terminals of CA1 neurons in the mouse dorsal hippocampus ([@B184]). Consideration should also be given to evidence suggesting that 5-HT~2A~R subunits are extensively and dynamically trafficked between the cytoplasm and the neuronal membrane, as much 5-HT~2A~R label has been identified at cytoplasmic rather than membrane bound compartments in adult rat neocortex ([@B40]). It will be of interest to determine the corresponding function of 5-HT~2A~R subunit trafficking between the respective neuronal sub-compartments, and the intracellular signaling that promotes trafficking.

Interacting Proteins
--------------------

Multiple interacting proteins regulate the function of 5-HT~2A~Rs in the membrane. 5-HT~2A~Rs interact with multiple PDZ protein-1 (MUPP1) and PSD-95 PDZ proteins ([@B79]). The 5-HT~2A~R colocalizes with PSD-95 and with MUPP1 in a subset of dendritic spines of rat cortical pyramidal neurons. PDZ proteins are vital for docking 5-HT~2A~R to the dendrites in cortical neurons and preventing the internalization of 5-HT~2A~Rs ([@B177]). MUPP1 is enriched in dendritic spine PSD domains of pyramidal neurons and enhances the localization of 5-HT~2A~R to the cell surface. Within cortical pyramidal neurons, PSD-95 regulates the functional activity of 5-HT~2A~R by promoting apical dendritic targeting and stabilizing receptor turnover. The complex of 5-HT~2A~R and PSD-95 plays a key role in 5-HT~2A~R-mediated head-twitch behavior in mice ([@B1]). Binding of calmodulin to the 5-HT~2A~R C-terminus impedes PKC-mediated phosphorylation of the 5-HT~2A~R, thus, preventing its desensitization ([@B163]). Conversely, association of p90-RSK2 with 5-HT~2A~R (intracellular 3 loop) silences the GPCR's signaling ([@B146]). Caveolin-1 interacts with 5-HT~2A~R and profoundly modulates its signaling by facilitating the interaction of 5-HT~2A~R with Gαq ([@B16]). 5-HT~2A~R and the light chain 2 domain of the microtubule-associated protein MAP1A are co-localized in the intracellular compartment of pyramidal neuronal dendrites of adult rats and may participate in intraneuronal signaling processes involving cytoskeletal elements ([@B41]). In consideration of these properties, we suggest that altering 5-HT~2A~R-coupled proteins and pathways may enable an alternative method to selectively promote distinct modulatory functions of 5-HT~2A~Rs.

Signaling
---------

Activation of neuronal 5-HT~2A~Rs can induce pleiotropic effects via G protein-dependent, ligand-dependent, and ligand-independent signaling pathways, including phospholipase signaling, ERK pathway, and tyrosine kinase pathway in neurons ([@B112]; [@B100]). In most circumstances, activation of 5-HT~2A~Rs increases intracellular Ca^2+^ levels via G~αq~-PLC-IP3 signaling ([@B65]). In PFC, activation of 5-HT~2A~Rs suppresses membrane Ca~v~1.2 L-type Ca^2+^ currents via a G~αq~-mediated PLCβ/IP~3~/calcineurin signaling pathway ([@B43]). 5-HT~2A~R activation also stimulates the G~α12/13~-phospholipase A2 signal transduction pathway, which promotes arachidonic acid release ([@B89],[@B90]).

Besides PLC-mediated Ca^2+^ signaling, 5-HT~2A~R activation also induces ERK phosphorylation via diverse intracellular signaling mechanisms ([@B61]). Src and calmodulin promote 5-HT2AR-mediated phosphorylation of ERK. In the PC12 cell model system, ERK phosphorylation by 5-HT~2A~R may not depend on PLC/PKC signaling, and instead requires an increase in intracellular Ca^2+^, and the activation of CaM and Src ([@B131]). The ERK target RSK2 directly acts on the third intracellular (i3) loop of 5-HT~2A~R protein ([@B146]), leading to direct phosphorylation of the i3 loop at the conserved residue Ser-314 to suppress 5-HT~2A~R signaling. In addition, RSK2 is required for tyrosine kinases, such as the epidermal growth factor receptor and the platelet-derived growth factor receptor, both of which have been demonstrated to attenuate 5-HT~2A~R functioning in primary cortical neurons ([@B158], [@B157]).

Besides the G protein, 5-HT~2A~Rs are also coupled to β-arrestin2. 5-HT binds 5-HT~2A~R to stimulate Akt phosphorylation via the β-arrestin2/phosphoinositide 3-kinase/Src/Akt cascade ([@B142]). Application of the 5-HT~2A~R agonist DOI to cultured cortical neurons induced phosphorylation of p21-activated kinase (PAK) via Rac guanine nucleotide exchange factor (RacGEF) kalirin-7 ([@B79]). The 5-HT~2A~R also regulates the tyrosine kinase pathway activity ([@B131]). Excitation of neuronal 5-HT~2A~Rs activates transglutaminase which leads to transamidation of Rac1, a small G protein, resulting in constitutive activation of Rac1 ([@B42]). Chronic treatment with olanzapine, an atypical antipsychotic drug, causes the desensitization of 5-HT~2A~R signaling. In rat frontal cortex, stimulation of the JAK-STAT pathway desensitizes the 5-HT~2A~R-mediated PLC activation induced by olanzapine ([@B150]). Furthermore, constitutive activation of 5-HT~2A~Rs induces G~q/11~ phosphorylation and desensitization (uncoupling) ([@B147]).

As indicated above, 5-HT~2A~Rs are also expressed in microglia and mediate 5-HT-induced exosome release ([@B57]). Activation of 5-HT~2A~R increases intracellular Ca^2+^ via PLC signaling in astrocytes ([@B65]) and Glu eﬄux from C6 glioma cells ([@B106]). Considering the diversity of signaling cascades that can be triggered by 5-HT~2A~R activation, it is perhaps not surprising that serotonergic activation of 5-HT~2A~Rs can have diverse influences on neuronal responses and CNS functions.

Oligomerization
---------------

The GPCRs can form homomers and heteromers, and thereby present distinct signaling and functional activities ([@B135]). Consistent with this, 5-HT~2A~Rs have been shown to form oligomers ([@B96]). Fluorescence resonance energy transfer and immunoprecipitation studies revealed that the human 5-HT~2A~R homodimerizes in cultured cells ([@B22]). For 5-HT~2A~R oligomers, the 5-HT~2A~R agonist DOI caused an increase in energy transfer efficiency to the level of 12%, and ketanserin caused a decrease of 4.4%. Heterodimers of 5-HT~2A~R and dopamine D~2~ receptors respond to DOI and quinpirole, a DA D~2~R agonist, with a decrease in FRET efficiency, while ketanserin and butaclamol increase the transfer efficiency value ([@B96]). Heterodimers of 5-HT~2A~R and mGluR2 receptor form via the linking domain in transmembrane-4 and -5 segments, and are present in the human brain. Post-mortem studies indicate a reduced density of these functional complexes in brains of schizophrenics ([@B59]). Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound of marijuana, induces memory impairments, anxiety, dependence, and analgesia. [@B169] recently reported that amnesic and anxiolytic effects, but not analgesia, induced by THC were suppressed in 5-HT~2A~R knockout mice. Molecular studies revealed that cannabinoid CB1 receptors (CB1R) and the 5-HT~2A~R physically interact with each other to form heteromers, which are distributed extensively in hippocampus, cortex, and dorsal striatum, but not in the NAc. *In vivo* experiments have revealed that stimulation of CB1R and 5-HT~2A~R reduces cell signaling, and the binding of an antagonist to one receptor blocks signaling of the interacting receptor. Heteromer formation leads to a switch in 5-HT~2A~R-mediated G-protein coupling from G~αq~ to G~i~. Synthetic peptides with the sequence of transmembrane helices 5 and 6 of CB1R disrupt CB1R and 5-HT~2A~R heteromerization *in vivo*, leading to a selective abrogation of memory impairments, but not the antinociceptive properties caused by THC exposure ([@B169]). The anatomy, biology and function of 5-HT~2A~R homomers and heteromers, including the dynamic formation and dissociation, distribution, signaling and function, remain elusive. Elucidation of 5-HT~2A~R oligomers will be interesting for both basic science research and potential clinical applications.

Allosteric Modulation
---------------------

Recent years have witnessed a tremendous advance in the research and development of novel compounds for GPCRs that bind allosteric sites to regulate receptor structure and function. These ligands provide high specificity, novel modes of efficacy and may open up a novel avenue for therapeutic agents against multiple mental and neurological disorders. Allosteric modulators bind to a site distinct from that of the orthosteric ligand-binding site. Usually the allosteric modulator induces a structure change within the GPCR to enhance or suppress the orthosteric ligand's functional activity ([@B39]; [@B105]). Application of the amidated lipid, oleamide significantly potentiated 5-HT-induced hydrolysis of phosphoinositide in pituitary P11 cells expressing endogenously 5-HT~2A~Rs ([@B161]). Taken together, these results indicate that there are several binding sites present on 5-HT~2A~Rs, and we suggest that it will be of interest to further characterize the functional significance of the distinct ligand-driven actions at the 5-HT~2A~R.

Constitutive Activity
---------------------

As mentioned above, 5-HT~2A~Rs can also be constitutively active (i.e., via activating the receptor in an agonist-independent activity) *in vivo* ([@B14]). The inverse 5-HT~2A~R agonists (e.g., risperidone and ketanserin) produce a great suppression of basal IP production, leading to a reduction of basal activity in the C322K mutant 5-HT~2A~R ([@B45]). The "constitutively active" arrestin mutant (Arr2-R169E) induces agonist-independent 5-HT~2A~R internalization, and a constitutive translocation of the Arr2-R169E mutant to the plasma membrane ([@B62]). The constitutive activity of 5-HT~2A~Rs may represent another mechanism of regulating cellular function. The specific relationships of these constitutively active 5-HT~2A~R-mediated properties to distinct behaviors have not been determined.

Electrophysiological Characteristics
------------------------------------

Electrophysiological studies reveal complex effects of 5-HT~2A~R activation on cortical neurons; however, mainly these receptors appear to mediate depolarizing effects on excitatory and inhibitory neurons. Slice recordings from prefrontal cortical neurons indicate depolarizing effects following 5-HT~2A~R activation ([@B3]; [@B185]; [@B11]). Local application of DOI, a 5-HT~2A/2C~ receptor agonist, increases the firing rates of cortical neurons ([@B155]) and facilitates synaptic plasticity through an NMDAR-dependent mechanism in presumptive pyramidal neurons of the rat BLA ([@B30]). Meanwhile, α-methyl-5-hydroxytryptamine (a 5-HT~2~R agonist) and DOI induce activation of GABAergic interneurons of the rat BLA ([@B155]). Double immunofluorescence labeling demonstrated that the 5-HT~2A~R is primarily localized to parvalbumin-containing BLA interneurons. Accordingly, 5-HT primarily acts on 5-HT~2A~Rs to potentiate GABAergic inhibition. 5-HT~2A~R activation increases the frequency and amplitude of sIPSCs recorded from the pyramidal neurons in BLA of the juvenile rat ([@B78]). DOI potentiates NMDAR-mediated changes in membrane potentials and calcium influx without affecting the neuronal resting membrane potential or input resistance. However, DOI does not affect AMPA/kainate receptor-mediated excitatory synaptic responses ([@B30]). The relationship of 5-HT~2A~Rs to NMDARs is consistent with the view that 5-HT~2A~Rs may be an effective target for modulating experience-dependent synaptic plasticity in the CNS. Globally, 5-HT~2A~Rs have been shown to influence low-frequency field potential oscillations in rat frontal cortex ([@B29]). Taken together, these findings demonstrate that the 5-HT~2A~R mediates 5-HT-induced excitation of cortical neurons. However, much remains to be determined as to the neurophysiological consequences of 5-HT~2A~R activation, in particular as they relate to the regulation of specific behaviors.

Recent molecular and pharmacological research has made significant advances in the understanding of the functional selectivity of 5-HT~2A~R. The multiple signaling pathways suggests bias agonism and bias signaling of 5-HT~2A~Rs, which posit that an agonist can produce a mix of signaling, which is potentially determined by cell type and functional status.

5-HT~2A~R Functions in CNS
==========================

Long-term declarative or episodic memory is supported by a network of brain structures in the medial temporal lobe of the mammalian brain. The medial temporal lobe memory system, which includes the hippocampus, dentate gyrus, and surrounding extrahippocampal cortical regions, influence decision-making processes guided by the PFC, and posterior parietal cortex ([@B153], [@B154]; [@B129]). Serotonergic fibers originating from the raphe nuclei innervate many of the critical nodes within the medial temporal lobe memory system, including the hippocampus and amygdala, and on to the PFC ([@B167]; [@B168]). The modulatory influence of 5-HT on simple and more complex forms of learning and memory has been extensively examined in both invertebrate and vertebrate model systems ([@B82]). The relevance of 5-HT to memory seems to generalize across mammals:, dietary tryptophan increases brain 5-HT levels and improves memory in rodents ([@B85]), the elderly, AD patients, and schizophrenics ([@B92]; [@B127]). Further, reductions in brain 5-HT concentrations after acute or chronic tryptophan depletion has been demonstrated to impair contextual fear memory in mice ([@B164]), object memory in rats ([@B77]), and declarative memory in humans ([@B144]). Below, we describe some evidence suggesting that the 5-HT~2A~R may hold special significance as one of the substrates by which 5-HT regulates learning and memory ([@B109]).

Learning and Memory
-------------------

Polymorphisms in the human *HTR2A* gene are associated with altered memory processes. For example, a *HTR2A* gene polymorphism inducing the substitution of the His452 on the receptor subunit to a Tyr residue is associated with a significant impairment in memory recall amongst adults ([@B44]; [@B149]; [@B186]). Carriers of the His452Tyr (rs6314) exhibited poor verbal delayed recall and recognition, but performed equivalent to controls on tests of immediate recall, attentional, and executive function ([@B170]). Compared to His homozygotes, Tyr carriers exhibited a diminished hippocampal response to novel stimuli and a higher tendency to judge novel stimuli as familiar during delayed recognition ([@B145]). Amongst schizophrenics and healthy controls, those carriers of homozygous CC (T102C) and GG (A-1438G), or carriers of the so-called *T*-allele (rs6314), of the *HTR2A* gene polymorphisms exhibited significantly impaired short-term verbal memory ([@B4]), and spatial working memory ([@B18]). Another polymorphism in the *HTR2A* gene, referred to as rs4941573 was found to be predictive of increased error rate in a spatial working memory task in an adult Chinese subject population ([@B58]). These results provide just a brief and incomplete view of a broad literature indicating the impressive degree to which alterations in the *HTR2A* gene relate to disordered cognitive functions in normal and abnormal human subjects.

The regional distribution of 5-HT~2A~Rs can be predictive of the memory capacities that are sensitive to serotonin manipulation. The 5-HT~2A~Rs are widely expressed in the neocortex and hippocampus of rats ([@B178]; [@B66]), rabbits ([@B6]), primates ([@B76]; [@B95]), and humans ([@B73]; [@B95]). **Table [1](#T1){ref-type="table"}** summarizes the major findings of studies in which the learning and memory effects were examined after 5-HT~2A~R pharmacological manipulations across distinct tasks and different species. The inconsistency of experimental results may be attributed to the species, selectivity and dose of drug, behavioral task and other effectors.

###### 

Reported effects on learning and memory after pharmacological manipulation of 5-HT~2A~ receptors (5-HT~2A~Rs).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                      Route; dose                       Task                                                      Species   Effect                                                 Reference
  ------------------------- --------------------------------- --------------------------------------------------------- --------- ------------------------------------------------------ --------------------------------------
  M100907                   0.01--0.1 mg/kg; i.p.             Probabilistic reversal learning                           Mice      ↑Acquisition                                           [@B7];\
                                                                                                                                                                                         ^∗^BTBR T+tf/J mouse model of autism

  M100907                   0.01--0.1 mg/kg; i.p.             Serial spatial reversal learning task                     Rats      ↓ Retrieval                                            [@B21]

  M100907                   0.02--2.0 nmol; olfactory bulb    Reversal-learning task                                    Rats      ↓ Acquisition                                          [@B54]

  MDL 11,939                0.067--6.7 μmol/kg; s.c.          Nictitating membrane conditioned responses                Rabbits   ↓ Acquisition                                          [@B173]

  MDL 11,939                300 ng/μl; mPFC                   NOR task                                                  Rats      ↓ Retrieval                                            [@B13]

  Ritanserin,               2.5 mg/kg × 11 days; s.c.         Conditioned olfactory training                            Rat pup   ↑ Acquisition                                          [@B104]

  Risperidone               1 mg/kg; i.p.                     Reward-dependent operant conditioning task                Rats      ↓ Acquisition and ↑ extinction                         [@B53]

  Risperidone               0.125 mg; i.p.                    Probabilistic reversal learning                           B6 mice   ↓ Acquisition                                          [@B7]

  Ketanserin Methysergide   1.0--3.0 mg/kg; s.c.;\            Delayed non-matching to position task (working memory)    Rats      ↔ Retrieval                                            [@B140]
                            3.0--15.0 mg/kg; i.p.                                                                                                                                        

  Ketanserin                0.1 mg/kg × 14 days; i.p.         Passive avoidance paradigm and MWM                        Rats      ↓ Acquisition                                          [@B49]

  DOI Ketanserin            0.01--0.1 mg/kg; i.p.\            Autoshaping learning task                                 Rats      ↑ Consolidation                                        [@B111]
                            0.001--0.1 mg/kg, i.p.                                                                                                                                       

  M100907;\                 PFC                               Oculomotor delayed-response tasks                         Monkeys   ↓ Acquisition\                                         [@B174]
  α-methyl-5-HT                                                                                                                   ↑ Acquisition                                          

  TCB-2                     1.0 mg/kg; i.p.                   NOR task and Trace and delay fear conditioning            Mice      ↑ Object memory acquisition; ↑fear memory extinction   [@B183]

  DOI                       0.1--0.3 mg/kg; i.p.              Autoshaping learning task                                 Rats      ↓ Consolidation                                        [@B109]

  LSD                       0.43--12.9 μg/side; hippocampus   Trace eyeblink conditioning.                              Rabbits   ↑ Acquisition                                          [@B136]

  LSD                       1--300 nmol/kg; i.v.              Nictitating membrane response                             Rabbit    ↑ Acquisition                                          [@B56]

  LSD                       0.13 mg/kg/d × 11 days; s.c.      Bulbectomy-induced deficit in active avoidance learning   Rats      ↑ Acquisition                                          [@B24]

  Psilocybin                215 μg/kg; oral                   Spatial working memory task                               Humans    ↔ Retrieval                                            [@B27]

  Psilocybin                0.1--1.5 mg/kg, i.p.              Trace fear conditioning -                                 mice      ↑ Extinction                                           [@B28]

  Psilocin                  1.0 mg/kg, i.p.\                  MWM;\                                                     Rats      ↓Acquisition of CM;\                                   [@B134]
                            4.0 mg/kg, i.p.                   Carousel maze (CM)                                                  ↓Retrieval of MWM (4 mg/kg);\                          
                                                                                                                                  ↔ Consolidation                                        

  Quipazine                 1.25--10 mg/kg, s.c.              Conditioned avoidance response                            Rats      ↑ Acquisition                                          [@B5]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

↑, enhance; ↓, suppress; ↔, no effect.

### Object Memory

The spontaneous NOR task, which relies on rodents' inherent preference for exploring novel over familiar stimuli, has become a popular method for examining the neuropharmacological and neurophysiological mechanisms of object memory ([@B48]; [@B38]). In the task, rodents are exposed to one or two novel objects in a familiar enclosure during a sample session (i.e., training). The rodent is removed from the enclosure after it has sufficiently explored the objects. After a delay of some length, the rodent is returned to the enclosure for a memory test session, during which the enclosure contains one familiar object and a novel object. If the rodent has successfully encoded and consolidated the memory of the original object from the sample session, then it is expected that the rodent will preferentially explore the novel object during the test session. The NOR task offers advantages for testing rodent memory in that the distinct memory processes of encoding, consolidation and retrieval are operationally defined as events occurring during the sample session, after the sample session, or during the test session, respectively. Another advantage is that the behavioral responses are spontaneous rather than requiring overt motivation such as electrical shock or food restriction. Our recent studies implicate the hippocampus as a key region in the rodent brain for object memory processes ([@B37]; [@B38]). In light of the fact that 5-HT~2A~Rs are densely expressed in the hippocampus ([@B97]), we examined the contribution of hippocampal 5-HT~2A~Rs in object memory processes in male mice using an NOR task (see **Figure [1](#F1){ref-type="fig"}**). Systemic activation of 5-HT~2A~Rs with the selective agonist, TCB-2 after the sample session significantly enhanced the time mice spent exploring the new object presented during the test session 24 h later ([@B183]). The memory-enhancing effect of TCB-2, was blocked by pretreatment with the 5-HT~2A~R antagonist, MDL 11,939, which suggests that 5-HT~2A~R activation enhances the consolidation of object memory. Interestingly, when TCB-2 was administrated before the sample session, or before the test session, the 5-HT~2A~R agonist failed to increase novel object preference relative to the respective control group. Together, these data suggest that 5-HT~2A~R activation selectively potentiates memory consolidation. Furthermore, the selective local microinfusion of TCB-2 into the CA1 region of dorsal hippocampus recapitulated the memory enhancing effect observed after systemic treatment ([@B184]). The relevance of the 5-HT~2A~R for object memory processes was also demonstrated by results of a study showing that the local infusion of the 5-HT~2A~R antagonist MDL 11,939 into the mPFC impaired retrieval of object-in-context memory in rats ([@B13]). Interestingly, the 5-HT~2A~R agonist DOI was found to impair retrieval of memory for an operant response by adult rats in an autoshaping task ([@B109]). Thus, it would appear that the influence of the 5-HT~2A~R on memory is task- and memory system-dependent, and perhaps by the underlying neural circuitry that supports the respective memory process.

![**Activation of 5-HT~2A~Rs enhances the consolidation of object memory. (A)** Experimental strategy. Left, during the sample session, mice were allowed to explore two identical novel objects each for at least 15 s, or either one for 18 s within a 10-min sample session. Middle, during the test session 24 h later, one of the objects (a cabinet leveling foot) was replaced with a novel object (a plastic toy monkey) and mice were individually reintroduced to the arena. Right, the objects used in this study. **(B)** There was no difference in the latency to achieve exploration criteria during the sample session between the saline- and TCB-2-treated mice. **(C)** Mice that received TCB-2 right after the sample session exhibited a significantly stronger preference for exploring the novel object during the test session: analysis revealed that TCB-2-treated mice had a higher mean discrimination ratio as compared to that of the saline group. **(D)** MDL 11,939, a selective 5-HT~2A~R blocker suppressed TCB-2-induced enhancement in object memory ([@B183]). ^∗^*p* \< 0.05, vs. respective control condition.](fphar-06-00225-g001){#F1}

The encoding and consolidation of hippocampal-dependent memory appears, in part, to require fast glutamatergic neurotransmission, ensuing phases of synaptic plasticity, and dynamic replay of experience-dependent neurophysiological oscillatory activity within hippocampal cell populations ([@B46]; [@B84]). Our published ([@B183]) data show that post-training activation of 5-HT~2A~R s enhances object memory, likely by affecting consolidation. Prevailing views state that the hippocampus transfers recent to-be-remembered information to the neocortex during sharp wave ripples of the hippocampal local field potential (i.e., 100--200 Hz ripples; [@B34]; [@B26]). During sleep, hippocampal neurons 'replay' patterns of spike trains present during a learning episode. As sharp wave ripples and replay may represent systems consolidation of memory, it would be of interest to examine the influence of 5-HT~2A~R-sensitive drugs on sharp wave ripples and replay of spiking sequences during sleep episodes after a to-be-remembered experience. Postsynaptic 5-HT~2A~Rs may modulate object memory consolidation by also influencing NMDAR-mediated synaptic plasticity. Consistent with this possibility, hippocampal 5-HT~2A~Rs are predominantly expressed at dendritic sites on pyramidal neurons ([@B40]; [@B122]). 5-HT~2A~R-containing dendritic processes also were immunolabeled for the NMDAR subunit NR1 and GluR2 ([@B122]). We have found that 5-HT~2A~R activation increased the extracellular eﬄux of glutamate in the dorsal hippocampus, and increased the basal firing rates of CA1 pyramidal neurons in awake behaving mice ([@B184]). These results suggest that the 5-HT~2A~R activation induced facilitation of object memory consolidation, may result from the potentiation of hippocampal glutamate release, and pyramidal neuron temporal dynamics at a critical post-training time period. These data suggest that the 5HT~2A~R may serve as a drug target for pharmacological interventions to treat memory impairments. It is conceivable that 5-HT~2A~R activation promotes an increase in intracellular Ca^2+^, combined with NMDAR-mediated Ca^2+^ influx, which together would facilitate the behavior-initiated synaptic plasticity. [@B3] reported that activation of 5-HT~2A~R produces an elevation in the frequency and amplitude of neuronal sEPSP/sEPSC. Consistently, 5-HT~2A~R activation has been shown to facilitate NMDAR activity and synaptic plasticity in the cortex ([@B9]) and BLA ([@B30]). Furthermore, 5-HT~2A~R directly interacts with PSD-95 to regulate receptor trafficking and signaling ([@B177]). 5-HT~2A~R activation induces a transient increase in dendritic spinogenesis ([@B179]), phosphorylation of PAK, neuronal Rac guanine nucleotide exchange factor ([@B79]), BDNF expression ([@B165]), and Erk mitogen-activated protein kinase activity ([@B52]; [@B172]). Finally, the 5-HT~2A~R inverse agonist pimavanserin was shown to reverse NMDAR antagonism-induced object memory impairments in combination with atypical antipsychotic drugs ([@B151]). These results support the view of a modulatory influence of 5-HT~2A~R on NMDAR-dependent memory mechanisms. Considering the myriad potential influences of 5-HT~2A~R on medial temporal lobe memory mechanisms, there would appear to be multiple downstream influences by which 5-HT~2A~R activation could enhance memory.

### Fear Memory

While there is a rich literature on the influence of serotonin on anxiety and an established contribution of serotonergic drugs to the remediation of anxiety disorders in humans, the present review will focus on the influence of 5-HT~2A~Rs on fear memory encoded during Pavlovian conditioning sessions. Pavlovian fear conditioning has become a popular procedure for examining the neurobiological mechanisms of fear memory. As a Pavlovian conditioning procedure, fear conditioning lends itself well to defining processes of encoding, consolidation and retrieval of fear memory. Fear conditioning taxes a well-defined neural circuit within the amygdala, which in turn interacts with the hippocampus, anterior cingulate, or the PFC, depending on the elements of the conditioning session and the stage of memory processing ([@B182]). In addition, considerable attention has been given to investigations of the underlying biology of extinction of fear memory. During a delay fear conditioning session, an innocuous stimulus (e.g., a neutral tone or light) becomes a CS when it is repeatedly presented in such a way that it co-terminates with the presentation of a sufficiently aversive US (e.g., foot shock) ([@B183]). The unconditioned response to the foot shock US is typically jumping and running, but the conditioned response to the CS is a defensive freezing response, or the cessation of all movement except for respiration. Thus, the freezing behavior provides a reliable post-conditioning measure of fear memory in rodents ([@B17]). During fear conditioning, the subject learns to associate the tone CS with the foot shock US, and under certain conditions, learns to associate the foot shock with the environment or context where the conditioning session was presented. Acquisition of both the tone-shock and the context-shock associations requires the amygdala; however, the context-shock associations are also dependent upon the hippocampus ([@B86]; [@B125]). There has been considerable debate regarding the involvement of the hippocampus in contextual fear memory since there have been reports that hippocampal lesions impair contextual fear memory ([@B86]; [@B125]; [@B8]; [@B156]), and others reporting that such lesions spare contextual fear memory ([@B31]; [@B176]). Consensus seems to be building for the view that if the rodent is permitted sufficient time to acquire a hippocampal-dependent configural representation of the context (the chamber's geometry, olfactory, visual, tactile, and auditory cues) before the US is presented, then the hippocampus is engaged in associating the contextual memory with the foot shock ([@B138], [@B139]; [@B101]; [@B182]). In a trace fear conditioning procedure, a temporal gap is imposed between the offset of the tone CS and the onset of the foot shock US. The acquisition of an appropriately timed (i.e., anticipatory) conditioned freezing response occurs progressively over the course of the repeated CS--US pairings; this temporal fear memory is a form of declarative memory dependent on intact hippocampal function in rodents and humans ([@B35]; [@B102]; [@B32]). It should be clear that in deciphering an influence of 5-HT~2A~R-sensitive drugs on the distinct processes of memory for contextual and/or cued fear, one must consider the specifics of the conditioning protocol used.

Finally, considerable attention has been directed toward defining the mechanisms of fear memory extinction, in part because of extinction's potential relationship to components of the human disorder post-traumatic stress disorder ([@B80]). Repeated presentations of the CS alone to the fear-conditioned rodent, promotes the acquisition of a new inhibitory association, which dampens or completely suppresses the expression of conditioned fear responses. Distinct subregions of the rodent PFC contribute differentially to fear extinction; that is, the prelimbic cortex appears to influence the expression of fear responses, while the infralimbic cortex influences the acquisition of extinction of fear memory ([@B133]; [@B148]). Synaptic plasticity within mPFC-BLA neuronal circuits is induced during fear extinction training, resulting in increased inhibition of CS-elicited activity of BLA extinction neurons ([@B69], [@B70]). Thus, converging evidence implicates the infralimbic and prelimbic cortices of the rodent brain and their differential projections to the amygdala sub-regions and to the hippocampus as contributing significantly to the synaptic plasticity that develops during the acquisition of fear extinction (see [@B162] for a recent review).

We found that systemic administration of the 5-HT~2A~R agonist TCB-2 (see **Figure [2](#F2){ref-type="fig"}**) significantly enhanced the acquisition of fear extinction in mice that had undergone trace fear conditioning or delay fear conditioning ([@B183]). Importantly, the 5-HT~2A~R agonist did not affect locomotor responses or baseline freezing in the mice. Therefore, the effect of TCB-2 on fear extinction appeared to be specific to facilitating the acquisition of the new inhibitory memory that suppressed fear expression. It is of interest to determine the site of action in the rodent brain at which TCB-2 works to facilitate fear extinction. In light of the plastic changes in neural circuitry that occur during the acquisition of fear extinction, it is possible that TCB-2 influences either the infralimbic cortical neurons or the "extinction neurons" of the BLA to facilitate fear extinction. Izumi and colleagues reported that an amygdala-selective reduction of 5-HT content via site-specific 5,7-DHT injection reduced the expression of conditioned fear responses in rats ([@B75]). While this finding is difficult to reconcile with our report that 5-HT~2A~R activation enhanced fear extinction, it is possible that the 5-HT denervation may have increased postsynaptic expression of 5-HT~2A~Rs in the amygdala, which might in turn impair the expression of fear. It is clear that further studies are needed to clarify the neurophysiological influences of 5-HT, and the 5-HT~2A~R in particular, on the neural circuitry supporting fear memory encoding, consolidation, retrieval, and extinction.

![**Stimulation of 5-HT~2A~Rs enhances the acquisition of extinction of trace fear memory. (A)** Left, a chamber for fear conditioning (Context A) and contextual fear memory test; right, Context B, a modified chamber with different color, context, light density, and odor for cued fear memory test. **(B)** Trace fear conditioning training procedure. After a 60-s habitation to Context A, a tone was presented for 15 s followed by 30 s stimulus-free interval, and then a 0.5-s, 0.75 mA foot shock (US) was presented. The CS--US pairing was repeated eight times with a 210-s intertrial interval (ITI). Mice were removed from the conditioning chamber and returned to their home cages 60 s after the final CS--US pairing. Trace fear conditioning extinction procedure. Sixty seconds after placing the mouse into the modified chamber, eight unpaired 15-s tone CS were presented with a 120-s ITI. **(C)** Mice that received TCB-2 (1.0 mg/kg, i.p.) before a trace fear memory extinction test exhibited accelerated acquisition of extinction as indicated by significantly lower freezing scores earlier in the course of extinction as compared to those of vehicle-treated mice. TCB-2 significantly decreased percent freezing from the second to eighth CS presentation ([@B183]).](fphar-06-00225-g002){#F2}

The influence of the 5-HT~2A~R on the extinction and reconsolidation of fear memory may have significant impact on the development of therapeutic approaches for subjects with fear memory invasion, such as phobias and post trauma stress disorder ([@B133]). For decades, the pharmacological manipulation of the 5-HT system has been a useful approach to treat emotional and mental disorders, such as depression and anxiety. Recent progress has suggested a promising therapeutic application of hallucinogenic 5-HT~2~ agonists to treat depression and anxiety ([@B63]). These results suggest that despite the historical stigma associated with 5-HT~2A~R activators as potential hallucinogens, such compounds may provide important medical potential for treating affective and cognitive symptoms associated with emotional and mental conditions.

Glutamatergic neurons in the amygdala, cortex and hippocampus are essential for memory extinction and reconsolidation. Local infusion of NMDAR antagonists into the BLA or CA1 region of hippocampus before extinction training suppresses fear memory extinction and reconsolidation ([@B12]; [@B159]). The NMDAR partial agonist [D]{.smallcaps}-cycloserine facilitates the extinction of fear memory ([@B171]; [@B91]). Knockout of NMDAR in hippocampal CA1 pyramidal cells exclusively impairs the establishment of conditioning between the CS and the US during a trace fear conditioning task. These results suggest that the CS representation and conditioning are entrained within hippocampus cell ensembles, probably via NMDAR-dependent synaptic plasticity ([@B103]; [@B74]). Recall that 5-HT~2A~Rs are expressed in the dendrites and dendritic spines of dentate gyrus neurons where NMDARs and AMPARs are assumed to be located ([@B122]). 5-HT~2A~R activation produces an elevation in the frequency and amplitude of cortical neuronal sEPSP/sEPSCs ([@B3]), facilitates NMDAR activity and synaptic plasticity in the cortex ([@B9]) and BLA ([@B30]). It is worth while to examine the degree to which NMDARs expressed in the infralimbic and prelimbic cortices contribute to the 5HT~2A~R-mediated enhancement in fear extinction.

Converging evidence demonstrates that activation of 5-HT~2A~Rs via systemic injection, or by local microinfusion, appears to enhance two forms of hippocampal-dependent memory in mice: object memory and conditioned fear memory. Administration of a selective 5-HT~2A~R antagonist alone was not found to significantly affect object memory or fear memory ([@B183]), suggesting that memory consolidation does not require serotonergic activation of 5-HT~2A~Rs and/or the antagonists do not affect the tonic effect the 5-HT~2A~R. Activation of 5-HT~2A~Rs with TCB-2 was also found to facilitate fear memory extinction in mice. These results offer promising support for the view that the 5-HT~2A~R may be an important new target for consideration in the search for mechanisms by which long-term memory can be enhanced in humans.

Hallucination vs. Spatial Cognition
-----------------------------------

### 5-HT~2A~R and Hallucination

Recent evidence suggests that activation of 5-HT~2A~Rs may promote experiencing visual hallucinations by increasing neuronal excitability and altering visual-evoked cortical responses ([@B87]). Hallucination is a type of misperception defined as the perception of an object without there being an object to perceive. Hallucinations are a significant characteristic found in a diversity of psychiatric and neurological states. Hallucinations can be triggered by at least three categories of drugs: psychedelics, (i.e., DOI, TCB-2, LSD, and psilocybin) via activation of 5-HT~2A~Rs, psychostimulants (i.e., cocaine or amphetamine) via activation of dopamine D2 receptors and dissociative anesthetics (i.e., phencyclidine or ketamine) via blockade of glutamate NMDARs. The signaling and behavioral responses to each hallucinogen are distinct from each other. Activation of 5-HT~2A~R is critical for the psilocybin (found in magic mushroom)-induced α oscillations, N170 visual-evoked potentials, and visual hallucinations ([@B87]).

5-hydroxytryptamine/serotonin is an endogenous neurotransmitter and is not considered hallucinogenic. Interesting, *N*-methyltryptamines, a metabolite of 5-HT, also presents high affinity for 5-HT~2A~R and can induce hallucinations in a manner independent of β-arrestin2/phosphoinositide 3-kinase/Src/Akt cascade ([@B142]). Signaling for hallucinogens is distinct. Lisuride (an antiparkinsonian agent) and LSD both bind cortical 5-HT~2A~R, and thereby regulate PLC activity. LSD signaling involves pertussis toxin-sensitive heterotrimeric G~i/o~ proteins and Src ([@B60]). Non-hallucinogenic agonists, for example lisuride, only stimulate cortical Gq in rats, whereas hallucinogens such as psilocybin (found in magic mushrooms), and LSD stimulate both G~q/11~ and G~i~ ([@B60]). The β-arrestin pathway is involved in hallucinogen-mediated head shake responses in rodents ([@B143]), and 5-HT induces a head shake response in mice via a β-arrestin-2-dependent signaling. However, the DOI invoked head shake behavior is not dependent upon β-arrestin-2 signaling. These findings suggest that the 5-HT~2A~R-β-arrestin interaction may be exclusively for endogenous 5-HT action. Further examination of hallucinogen-mediated signaling may have major implications in drug development for treating emotional and mental disorders such as depression and schizophrenia ([@B143]). More research efforts will need to be focused on the hallucination-inducing aspects of 5-HT~2A~R-sensitive drugs and, relevant to their potential therapeutic potential, it may be important to consider designing novel compounds that yield more of the beneficial effects, without activating those problematic sensory and perceptual effects.

### 5-HT~2A~R-mediated Hallucination and Spatial Cognition

5-HT~2A~ receptors may affect spatial cognition. A human population-based study shows that 5-HT~2A~R TT genotype of rs6313 is associated with better spatial cognitive performance ([@B58]). [@B83] reported that the 5-HT~2A~R agonist DOI (0.1 and 0.25 mg/kg, 30 min pretreatment) slowed rat performance as assessed by swim time on both a well-learned water maze as well as learning of a new maze, but DOI did not alter error rate on either task. Kant concluded that DOI impaired performance by suppressing motor activity on a water maze ([@B83]), which was in opposition to another report showing that manipulation of 5-HT~2A~R did not impair the latency to a visible platform water maze test ([@B118]). The serotonergic hallucinogens may impair the hippocampal-dependent spatial cognition by acting on 5-HT~2A~Rs ([@B118]). However, the direct evidence of 5-HT~2A~R on visuospatial cognition and the central target has not been determined.

Serotonergic psychedelics may affect the integrity of visual functioning. Visual-directed spatial cognition and navigation are guided by exteroceptive (e.g., landmarks) and interoceptive (e.g., self-motion information) cues, and their integration. The hippocampus is a pivotal brain region receiving and integrating information for spatial memory and navigation in rodents ([@B23]; [@B47]). The MWM is a classic behavioral task for testing hippocampal-dependent visuospatial cognition, including place learning and memory, orientation and decision-making ([@B116]; [@B115]). Further, hippocampal place cells exhibit location-specific firing, and are considered to be fundamental components of network for spatial problem solving in the mammalian brain (for a review see [@B117]). The hippocampal neural circuit representing current location, directional heading and its integration is influenced by exteroceptive and interoceptive cues, and is considered to guide spatial cognition and navigation.

We recently found that pre-test activation of 5-HT~2A~R with TCB-2 significantly delayed the initiation of an accurate search path by well-trained male mice in the hidden platform MWM ([@B184]). Importantly, 5-HT~2A~R activation did not affect swim performance or visual cue-triggered approach behavior in the visible platform water maze task. Taken together, our results suggest that the activation of 5-HT~2A~R impairs the retrieval of hippocampal spatial memory, but not the accuracy of spatial information retrieval and decision-making. It is conceivable that the delayed initiation of accurate spatial search by TCB-2-treated mice might reflect the possible visual hallucinatory influences of the 5-HT~2A~R agonist. For example, perhaps TCB-2-induced a brief aberration of visual input that slowed the perception of current position and local view of the mouse at the start of the water maze probe test. Once, reconciled or reoriented, the mouse was able to swim accurately to the remembered spatial location of the platform. It will be of interest to determine where in the brain TCB-2 is acting to alter spatial memory retrieval. The relatively weak influence of TCB-2-induced visual hallucination on spatial navigation may due to the difference in the visual information passing through the brain and central targets processing the information.

Taken together, the results we have reported here of memory effects after activation of the 5-HT~2A~R represent a fairly complex picture. The post-training administration of TCB-2 enhanced consolidation of object memory in mice. Pre-test administration of TCB-2 did not affect retrieval of object memory, yet delayed retrieval of spatial memory. Pre-extinction training administration of TCB-2 facilitated the acquisition of extinction of both trace and delay fear memories. The facilitating effect of TCB-2 on fear extinction may have been the result of a combined effect of suppressing fear expression -- possibly a consequence of impaired retrieval of fear memory, and enhancing the encoding and consolidation of fear extinction. To characterize the 5-HT~2A~R agonist as a cognitive enhancer based solely on our object memory results, would be to ignore the other experimental findings. We are interested in conducting a more comprehensive analysis of the impact of TCB-2 on multiple forms of memory. For example, it will be interesting to examine whether post-conditioning TCB-2 might enhance the consolidation of fear memory, in a manner consistent with that observed in the NOR task. Likewise, it will be interesting to test whether post-extinction training TCB-2 facilitates the consolidation of fear extinction. Results of these experiments will help in better appreciating the modulatory influence of the 5-HT~2A~R on long-term memory processes. This synthesis of recent findings of the influences of 5-HT~2A~R activation should provide a credible argument that the 5-HT~2A~R participates significantly to the well-documented contribution of 5-HT to memory ([@B110]).

5-HT~2A~R and Mental Disorders
------------------------------

A number of psychiatric and neurodegenerative disorders are associated with the variation of structure, expression, and function of 5-HT~2A~Rs. Positron emission tomography (PET) molecular imaging has the sensitivity to quantify binding of 5-HT~2A~Rs in CNS disorders. Medication-free depressed subjects presented greater 5-HT~2A~R binding ([@B15]). There was a significant reduction in 5-HT~2A~R binding in frontal polar, dorsolateral and medial frontal cortex, and parietal and temporal associative cortex of OCD patients and a significant correlation between 5-HT~2A~R availability in orbitofrontal and dorsolateral frontal cortex and clinical severity ([@B123]). Schizophrenia patients present with very high 5HT~2A~R occupancy in the frontal cortex ([@B160]). These results suggest that the variation in the number, affinity and/or function of 5-HT~2A~R participates in the etiology of mental disorders.

### Alzheimer's Disease

It is interesting to note that neocortical 5-HT~2A~R binding is significantly decreased in patients with early stage AD, and in those with mild cognitive impairment; especially in temporal lobe regions associated with long-term memory ([@B107]; [@B67]; [@B141]; [@B99], [@B98]). Further, the severity of cognitive impairment in AD patients correlates with the decrease in 5-HT~2A~R binding ([@B166]). Given the pattern of 5-HT~2A~R distribution in neocortical regions and their expression on principal excitatory neurons, it is possible that the marked reduction in 5-HT~2A~R in brains of AD is a direct product of neuron loss in key brain regions. Consistent with evidence from the human studies, the Alzheimer's-like neuropathology and associated memory deficits in rodents, which follow intra-hippocampal injection of ß-amyloid(1-42), are associated with a significant reduction in levels of hippocampal 5-HT~2A~R expression ([@B33]). Although we have focused this analysis on the influence of 5-HT~2A~Rs on long-term, hippocampal-dependent memory, there is clear and compelling evidence to suggest that the 5-HT~2A~R represents a potential new target by which human long-term memory may be modulated. We assert that it will be of interest in further examine the contribution of 5-HT~2A~Rs to memory processes, and we are particularly interested in determining neurophysiological influences of 5-HT~2A~R agonists which promote the enhancement of memory consolidation which we have reported in mice.

### Drug Memory

Drug dependence, classified as an impulsive, compulsive, and relapsing psychiatric disorder, represents a devastating societal problem worldwide. The profound symptoms of drug abuse, in particular the cue-elicited relapse to drug use after even long periods of abstinence, are a consequence of robust experience-dependent synaptic plasticity within the brain's reward circuit. Like episodic, semantic, and habit memory, drug-associated memories are persistent and hold a strong influence on current and future behaviors. Of particular interest is the consideration of memory extinction as a psychological tool for remediating the problem of relapse in drug addicts. That is, if the problem of drug abuse is approached as a mental disorder of memory, then pharmacological manipulations that facilitate extinction may hold therapeutic utility for treating drug abuse. Drug exposure alters the expression and function of 5-HT~2A~R, for example morphine decreases frontocortical 5-HT~2A~R binding affinity in dogs ([@B2]). 5-HT~2~Rs are up-regulated in amygdala, midbrain, pons, and medulla of morphine-tolerant and -dependent rats, but not in morphine-abstinent rats ([@B64]). There is considerable evidence that 5-HT~2A~Rs modulate the behavioral consequences of repeated exposure to addictive psychomotor stimulants. For example, M100907 suppresses hyperactivity elicited by cocaine ([@B50]), MK-801, amphetamine ([@B120]), and morphine ([@B10]). DOM, a 5-HT~2A~R agonist, attenuates locomotor-stimulating effects of morphine, which could be prevented by M100907 ([@B93]). Furthermore, M100907 attenuated the ability of experimenter-administered cocaine to reinstate lever pressing ([@B50]) and attenuated the drug associated cue-induced reinstatement of cocaine-seeking behavior after extinction ([@B119]). M100907 also suppressed reinstatement induced by nicotine prime or nicotine-associated cue ([@B51]) and sensitization ([@B180]). Intra-NAc infusions of M 100907 blocked the expression of cocaine-induced locomotor sensitization ([@B181]). Intra-PFC M100907 decreased cue-elicited reinstatement of cocaine seeking-behavior ([@B126]). Together, these results suggest that 5-HT~2A~Rs modulate drug addiction-dependent behaviors such as craving and drug-seeking and pharmacological blockade of 5-HT~2A~Rs may represent a therapeutic advance in suppression of cue-evoked craving and/or relapse in drug addicts.

### Therapeutic Application of 5-HT~2A~R

Preclinical and clinical studies have provided support for the use of pharmacological manipulation of 5-HT~2A~R to treat the symptoms of mental disorders. Activation of 5-HT~2A~R with TCB-2 in the medial septum-diagonal band of Broca complex enhances neuronal activity and working memory in hemiparkinsonian rats ([@B94]). M100907 had no effect on attentional performance, but abolished the PCP-induced attentional performance deficits in rats ([@B128]). M100907 prevents impairment in attentional performance by NMDAR blockade in the rat PFC ([@B114]). There are a number of 5-HT~2A~R drugs that have been evaluated or are being currently evaluated under clinical trials, for example quetiapine^[1](#fn01){ref-type="fn"}^ for schizophrenia; M100907^[2](#fn02){ref-type="fn"}^ for depression; ACP-103^[3](#fn03){ref-type="fn"}^ for Parkinson's disease; pimavanserin for patients with AD psychosis^[4](#fn04){ref-type="fn"}^ or with Parkinson's disease psychosis^[5](#fn05){ref-type="fn"}^.

Conclusion
==========

In this review, we have summarized recent progress in the signaling, polymerization and allosteric modulation of 5-HT~2A~R; and have discussed the critical role of 5-HT~2A~Rs in a number of cognitive processes. Based on the results of studies from our lab and others, it appears that activation of 5-HT~2A~Rs may offer a novel approach to treat the impairment of learning and memory associated with several neurodegenerative disorders. Meanwhile, blockade of 5-HT~2A~R may offer a feasible way to suppress drug craving and/or relapse. It will be very interesting to identify the corresponding signaling pathways by which 5-HT~2A~Rs modulate these behavioral capacities. Of particular note, we reviewed evidence that 5-HT~2A~Rs may dimerize with other receptors, and that certain pathways may promote constitutive activation of 5-HT~2A~Rs, which likely represent novel receptor signaling influences. Connecting such novel properties of 5-HT~2A~Rs to distinct functional consequences of 5-HT-, or agonist-, specific activation of the 5-HT~2A~Rs will be important for improving understanding the myriad influences of 5-HT~2A~Rs in the CNS. The development of highly selective 5-HT~2A~R ligands will be essential for further establishing the critical involvement of the 5-HT~2A~R for a number of fundamental cognitive behaviors.
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5-HT

:   5-hydroxytryptamine/serotonin

AD

:   Alzheimer disease

AMPAR

:   alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor

BLA

:   basolateral amygdala

CS

:   conditioned stimulus

DOI

:   1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane

ERK

:   extracellular signal-regulated kinases

GFAP

:   glial fibrillary acidic protein

GPCR

:   G protein-coupled receptor

IP2

:   inositol phosphate

LSD2

:   lysergic acid diethylamide

mGluR2

:   metabotropic glutamate receptor

MUPP1

:   multiple PDZ protein-1

MWM

:   Morris water maze

NAc

:   nucleus accumbens

NMDAR

:   *N*-methyl-[D]{.smallcaps}-aspartate receptor

NOR

:   novel object recognition

OCD

:   obsessive--compulsive disorder

PDZ

:   postsynaptic density zone

PFC

:   prefrontal cortex

PKC

:   protein kinase C

PLC

:   phospholipase C

PSD

:   postsynaptic density

RSK2

:   ribosomal S6 kinase 2

sIPSC

:   spontaneous inhibitory postsynaptic current

sIPSP

:   spontaneous inhibitory postsynaptic potential

US

:   unconditioned stimulus
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